retatrutide triple agonist gip glp-1 glucagon phase 3 2025 10mg | GLP-1/GIP/Glucagon ADA 2026: Retatrutide Revolution

Avoiding sudden dietary changes and allowing 12 weeks between dose increases gives your nervous system time to adapt

Patients typically benefit from a slower ramp-upbeginning with lower starting doses and extending the interval between dose increases to allow the gut to adapt

Improvement in gastrointestinal symptoms after cognitive behavior therapy for refractory irritable bowel syndrome

Powder fiber supplements are messy and inconvenient, needing water, mixing, and timing

Ozempic is approved for blood sugar control and may help lower your risk of complications from heart disease, such as heart attack or stroke

(2025 update) As of April 2025, there is no FDA-approved generic version of semaglutide (the active ingredient in Ozempic and Wegovy) available in the United States